- Catalent has agreed to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a European CDMO.
- The sale is expected to close in early 2025, and Catalent’s corporate headquarters will remain at the Somerset site temporarily.
Catalent, Inc. has signed a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, New Jersey, to Ardena, a contract development and manufacturing organisation (CDMO). Ardena operates facilities in Belgium, Spain, the Netherlands, and Sweden. The transaction is expected to close in early 2025, with financial terms not disclosed.
The Somerset site also serves as Catalent’s corporate headquarters, which will remain at the location during a transition period. A new headquarters location will be announced at a later date.
This divestiture follows Catalent’s recent investments in its oral solids capabilities across other sites in the United States and Europe. These include expansions in high potent API handling, spray drying technologies, and additional manufacturing capacity. The most notable development came in October 2022, when Catalent acquired a 333,000-square-foot facility in Greenville, North Carolina, for $475 million. The Greenville site specialises in oral solid dosage forms, providing formulation development, analytical services, and packaging solutions.
Commenting on the move, Catalent stated that the sale aligns with its strategy to optimise resources across its global network.
Overview of outsourcing trends 
